Davide Ancelotti tells Rangers he's ready to rock as manager target left excited by Andrew Cavenagh talks
Ancelotti desperately wants the job and has put Rangers ahead of offers from back home in Italy
Davide Ancelotti has told Rangers bosses he's ready to step out of his legendary father's shadow and be a success in his own right.
The Ibrox club are set to make a next boss call on Ancelotti or Russell Martin in the early part of next week as the American revolution swings into action.
Rangers' new US owners completed their takeover on Friday and are preparing to name their man after holding a final round of talks this weekend.
Ancelotti desperately wants the job and has put Rangers ahead of offers from back home in Italy including newly-promoted Serie A side Pisa.
The 35-year-old has been assistant to his dad Carlo at Bayern Munich, Napoli, Everton and most recently Real Madrid. He could have followed his old man who has now taken over the Brazil national side.
But having mulled over his future last week on a family holiday, Ancelotti has decided he is ready to take the next step and become an outright number one.
It's understood the fresh start under new owners Andrew Cavenagh and 49ers Enterprises excites the Italian who has sold his Ibrox blueprint on the club in a series of interviews.
New sporting director Kevin Thelwell officially starts work on Monday morning - which will mark 99 days since Philippe Clement was sacked - and is set to make a final decision in the coming days.
Thelwell has been leading the hunt backed by 49ers Enterprises technical director Gretar Steinsson.
Former Southampton boss Martin is also understood to have impressed in interviews.
Martin was sacked by Saints in December with the club bottom of the Premier league on just five points from 16 games but feels ready to jump back into top level management.
Francesco Farioli and Brian Priske had also been sounded out while Steven Gerrard took himself out of the running after talks.
The new boss will be backed to the tune of almost £20m under the new owners' initial investment.
They know the clock is ticking on getting a squad in place and ready to hit the ground running with the qualifiers for the Champions League just 51 days away.
Rangers players return for pre-season training on June 23, the same day as an EGM has been arranged where shareholders will be asked to approve the £20m investment.
You can get all the news you need on our dedicated Rangers and Celtic pages, and sign up to our newsletters to make sure you never miss a beat throughout the season.
We're also on WhatsApp where we bring all the latest breaking news and transfer gossip directly to you phone. Join our Rangers community here and our Celtic community here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
28 minutes ago
- Daily Mail
Stop denying thousands of women with incurable breast cancer wonder drug that could boost survival almost 50%, NHS urged
A lifeline drug currently denied to thousands of women with incurable breast cancer could boost survival by almost 50 per cent, pivotal new research has suggested. Medics hailed the drug Enhertu after the trial showed it could extend the lives of patients with one of the hardest to treat forms of the disease, buying them an extra year or more of life. Campaigners said the new findings add to the 'betrayal' that they cannot get the life-extending treatment on the NHS in England or Wales when it is already available in Scotland. It follows repeated decisions by NHS spending watchdog the National Institute for Health and Care Excellence (NICE) to deny the 'wonder drug' on cost grounds using new criteria which does not class all terminal cancers as 'severe'. Also known as trastuzumab deruxtecan, it is a targeted treatment for patients with a an aggressive and fast-growing type of cancer, known as HER2-positive—accounting for roughly one in five cases of the disease. Researchers presenting the findings at the American Society of Clinical Oncology conference in Chicago said it showed Enhertu was a 'highly effective' drug that should become the first port of call for patients with this form of breast cancer. In the trial, women taking the drug alongside another treatment called pertuzumab, lived without their cancer growing for 40.7 months on average, compared to just 26.9 among those who took standard treatment—the drug trastuzumab and pertuzumab. Enhertu slashed the risk of death or the disease progressing by 44 per cent, they added. After two years, around 70 per cent of patients on the new combination had not seen their cancer grow or spread, compared to around 52 per cent on standard treatment. For those who had received the combination, 85 per cent saw their cancer shrink or disappear compared to 78.6 per cent in the standard treatment group. Dr Sara Tolaney, head of breast oncology at the Dana-Farber Cancer Institute in Boston and study lead author, said: 'This trial has the potential to establish a new first line treatment for advanced HER2-positive breast cancer, a setting which hasn't seen significant innovation in more than a decade. Trastuzumab deruxtecan is a 'highly effective' and 'promising' therapy, she added. Around 1,000 women each year in England could benefit from the drug, which patients described as 'the last roll of the dice'. Last year, after NICE prevented the drug from receiving NHS funding—a decision the charity Breast Cancer Now called 'a dark day for women with incurable breast cancer'—one 46-year-old patient told how Enhertu would give her more time with her seven-year-old daughter Grace. Former marketing professional, Kathryn Hulland, who lives in Devon, was diagnosed with breast cancer in 2020 and underwent chemotherapy and surgery to remove the tumour. She responded well, but at Christmas 2022 she found a lump on her neck and was told her cancer had returned and spread. Checking your breasts should be part of your monthly routine so you notice any unusual changes. Simply rub and feel from top to bottom, in semi-circles and in a circular motion around your breast tissue to identify any abnormalities She said: 'If my chemo stops working, there won't be many treatments left.' She added: 'Six months more with her would mean the world. It's heartbreaking that patients in Scotland can get it, but I can't. It's a lifeline I can't reach.' Following NICE's decision, in an unusual move the watchdog hit out at AstraZeneca, the British firm who manufactures Enhertu, accusing it of being 'unwilling to offer a fair price'. But the pharmaceutical giant said the drug—believed to cost about £120,000 a year per patient—was available in 18 other European countries, including Scotland. Breast cancer specialist and author Dr Liz O'Riordan told MailOnline today: 'This trial yet again shows the huge benefits Enhertu can offer women, giving them vital extra months and years. 'This postcode lottery is so unfair. It's a betrayal to patients in England and Wales that they cannot access Enhertu, when it is already available in Scotland. 'What more will it take for it to be approved.' Dr Catherine Elliott, director of research at Cancer Research UK, meanwhile told MailOnline: 'Treatments that target HER2-positive metastatic breast cancers have transformed outcomes for many people but most still see their cancer progress within two years of starting treatment. 'These trial results suggest that adding Enhertu to the standard treatment could prevent or slow the growth of this type of breast cancer beyond three years. 'Importantly, people given this treatment were also more likely to see their tumour shrink or disappear.'
Scottish Sun
32 minutes ago
- Scottish Sun
Chelsea Champions League winner Salomon Kalou reveals surprising new business after retirement from football
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) EX-CHELSEA forward Salomon Kalou, 39, has stunned fans by revealing his new venture - running a chocolate business. The former Ivory Coast international, best known for helping the Blues lift the Champions League in 2012, has traded boots for sweet treats. Sign up for Scottish Sun newsletter Sign up 3 Salomon Kalou (right) spent seven seasons at Chelsea Credit: Getty 3 He was part of a Chelsea side that conquered Europe for the first time Credit: AP:Associated Press 3 The Ivorian has always had a thing for unusual hairstyles Credit: INSTAGRAM His brand is called Oume, named after his birthplace in the Ivory Coast with Kalou keen to emphasise the importance of his homeland in the chocolate world. He told The Telegraph in an interview: "My uncle had a cocoa farm, and I grew up around the farm. "We went to school and at the weekend we would be helping him. "Growing up, I don't remember eating chocolate and didn't know what it was. READ MORE FOOTBALL NEWS CHAMPING AT THE BIT Fergie arrives at CL final as his £2m-a-year Man Utd role ends "It was expensive more of a privilege for people who can afford to buy it. "People don't know that what they produce on their farms is used for chocolate. "But we (Ivory Coast) contribute a big percentage of the world's production. We also have great footballers." The surprise career move has raised a few eyebrows among fans who remember the pacy winger's dazzling runs down the Stamford Bridge flanks - not cocoa beans and hand-tempered truffles. BEST ONLINE CASINOS - TOP SITES IN THE UK Kalou, who also enjoyed spells at Lille, Hertha Berlin and Botafogo, says he hopes to one day see his chocolate in some of the UK's most prestigious shops. From embarrassing Chelsea pal to interview with dad - Five times Cole Palmer stole show AFTER Conference League finals He added: 'One day I'd like to see Oume in Waitrose, Selfridges, or Harrods. That would be a proud moment. "It is a tough market with the price of cocoa increasing due to extreme weather and under-investment.' The Ivorian started and won the Champions League final with Chelsea in 2012, making a total of 254 appearances for the Blues.
STV News
32 minutes ago
- STV News
New Rangers chief hopes for manager appointment 'in coming days'
New Rangers sporting director Kevin Thelwell says the appointment of a new head coach is his top priority and he hopes to confirm a deal in 'the coming days'. Thelwell, formerly director of football at Everton, officially started in his new role on Monday, days after the US takeover of Rangers was confirmed. The 51-year-old said he was aiming to move things forward quickly at the club, and that appointing a permanent successor to Philippe Clement was top of his to-do list. 'It's a great honour to be joining Rangers, particularly at such an exciting moment in the club's history,' Thelwell told Rangers' official website. 'While there has been significant work going on in the background prior to my arrival, that naturally accelerates from today, and top of the priority list will be the appointment of a new Head Coach for our men's first-team. 'That search has been progressing well, and the club and I look forward to bringing that to a conclusion in the coming days. 'This is a new chapter for Rangers, and while we recognise success won't come easy, our goal is clear: we need to win. 'My focus is on delivering that, with discipline and ambition. We'll give everything to move this club forward as quickly and sustainably as we can.' The Ibrox club also confirmed that Nils Koppen will leave his job as technical director after a handover period, with former Everton recruitment head Dan Purdy appointed as his replacement. Thelwell's first day on the job also saw him appointed to two key SFA and SPFL committees. The sporting director will sit on the Compensation Tribunal Working Group, as well as the SPFL Competitions Working Group, which is responsible for reviewing the competitive structure of the league and League Cup. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
